SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-024646
Filing Date
2022-02-17
Accepted
2022-02-17 14:05:21
Documents
14
Period of Report
2022-02-17
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm227066d1_8k.htm   iXBRL 8-K 24257
2 EXHIBIT 99.1 tm227066d1_ex99-1.htm EX-99.1 19951
6 GRAPHIC tm227066d1_ex99-1img01.jpg GRAPHIC 15157
  Complete submission text file 0001104659-22-024646.txt   243411

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA srne-20220217.xsd EX-101.SCH 3069
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE srne-20220217_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE srne-20220217_pre.xml EX-101.PRE 22619
8 EXTRACTED XBRL INSTANCE DOCUMENT tm227066d1_8k_htm.xml XML 3486
Mailing Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121
Business Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121 858-203-4100
Sorrento Therapeutics, Inc. (Filer) CIK: 0000850261 (see all company filings)

IRS No.: 330344842 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36150 | Film No.: 22647178
SIC: 2836 Biological Products, (No Diagnostic Substances)